Program

Wednesday September 26th

 Arrival in the afternoon. 

 Registration opened at 17:30

18:30 Opening of the workshop
  Organizing committee
18:35 - 18:45

 

Presentation of the "Tumour targeting & Radiotherapies network" of the Cancéropôle Grand Ouest

  Dimitris Visvikis, LaTIM, National Institute of Health & Clinical Sciences, Brest, France.

 

18:45 - 19:05

 

Sponsors communications

 

“When chelates make the différence in targeted PET imaging and radiotherapy with radiometals”  -  EASYCHELATORS

 

19:05 - 20:00

 

"Nanogalenic and therapeutic innovation"

  Invited speaker: Patrick Couvreur, Institut Galien, UMR CNRS 8612, Paris Saclay University, Chatenay Malabry, France.
   
20:15 Dinner

Thursday September 27th

Session 1: How to identify an adequate target?

Session 1a: How to identify a tumour target?

9:00 - 9:30

 

"Hit-finding strategies: from high-throughput screening to DNA-encoded libraries"

  Invited speaker: Alexander Satz, Roche, Switzerland.
   

9:30 - 10:30

 

“Contribution of molecular modelling to the development of virus-like particles for breast cancer theranostics“
  Rita Melo, Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Portugal.
   
  “Synthesis and biological validation of macrocyclic CXCR4 and ACKR3 binding agents for PET imaging and therapeutic applications in cancer”
  Isaline Renard, Department of Chemistry and Positron Emission Tomography Research Centre, University of Hull, United Kingdom.
   
  "Radiobiological characterization of 64CuCL2 for prostate cancer theranostics"
  Joana F. Guerreiro, C2TN - Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Portugal.
   
10:30 - 11:00 Poster session & Coffee break
   

11:00 - 12:00

 

“A versatile nanoemulsion for functionalization with different specific ligands for targeted drug delivery”

  Sainza Lores, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
   
  “New approaches for the utilization of Affibody molecules in cancer therapy: reviving an old dream”
  Mohamed Altai, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
   
  “Combining 2D angiogenesis and 3D Osteosarcoma microtissues to improve vascularization”
  Hassan ChaddadINSERM, UMR 1260, Regenerative Nanomedicine, FMTS & Université de Strasbourg, Hôpitaux Universitaires de Strasbourg (HUS), Strasbourg, France.
   
12:00 - 12:10 Sponsor communication - MILabs
   
12:15 Lunch
   
Session 1b: How to choose a target for antitumour immune response?
   

14:00 - 14:30

 

"MELOE-1 antigen: a model of immunogenic target for melanoma immunotherapy"

 

Invited speaker: Nathalie Labarrière, CRCINA, INSERM, Université d’Angers, Université de Nantes, Nantes, France.

 

14:30 - 15:30

 

“Relationship between the Location of Intraprostatic Hybrid Tracer Deposition and Lymph Node Visualization“
 

Clarize. M. de Korne, Interventional Molecular Imaging Laboratory, Department of Radiology, University Medical Center, Leiden, The Netherlands.

   
  “Inactivation of PD-1 gene in melanoma-specific CD8+ T lymphocytes”
  Lucine Marotte, CRCINA, INSERM, Université d’Angers, Université de Nantes, Nantes, France.
   
  “Alpha-Radioimmunotherapy targeting PD-L1 in melanoma“
 

Marisa Fernandes - Capitao, CRCINA, INSERM, CNRS, Université d’Angers, Université de Nantes, Nantes, France, France.

   
15:30 - 16:00 Coffee break
   
16:00 - 17:00 “A novel strategy to identify melanoma antigens from long non coding RNA“
  Emilie Dupré, CRCINA, INSERM, Université d’Angers, Université de Nantes,  & Labex IGO, Nantes, France.
   
  “Impact of RIT-alpha on the tumor microenvironnement“
  Justine Perrin, CRCINA, INSERM, CNRS, Université d’Angers, Université de Nantes, Nantes, France.
   
  “The inflammasome of tumor cells in colorectal cancer: a potential target to strengthen the Th1/Tc1 response of tumor infiltrating T lymphocytes (TILs)”
  Linda Bilonda, Institut Roche, Boulogne-Billancourt, France & CRCINA, INSERM, Université d’Angers, Université de Nantes, Nantes, France.
   
20:00 Dinner

Friday September 28th

Session 2: What are strategies to reach a tumour target?

9:00 - 9:30

“Peptides like drones: identify and reach the target"

 

Invited speaker: Stefania Galdiero, Department of Pharmacy, University of Naples “Federico II”, Italy.

 

9:30 - 10:30

 

“Self-assembly of prodrugs formed by cell-penetrating peptide and ferrocifen for lung cancer treatment”
 

Léna Guyon, MINT, Inserm U1066/CNRS 6021, Angers, France.

   
 

“Down-regulation efficiency and intracellular trafficking of siRNA nanovectors for triple negative breast cancer treatment“

 

Sanaa Ben Djemaa, EA6295 Nanomédicaments et Nanosondes, University of Tours, France.

   
 

“Targeting melanoma tumor cells with pH-responsive lipid nanocapsules: in vitro and in vivo studies”

 

Vincent Pautu, MINT, UNIV Angers, INSERM 1066, CNRS 6021, Université Bretagne Loire, Angers, France.

   
10:30 - 11:00 Poster session & Coffee break
   

11:00 - 12:00

 

“Magnetic NPs for breast cancer targeting: Controlling single-chain variable fragment antibody orientation during bioconjugation”
  Colin Moore, EA6295 NMNS, Université de Tours, France.
   
  “Paclitaxel/SPIO-loaded PLGA-based nanoparticles for the imaging and therapeutic targeting of glioblastoma”
  Lakshmi Pallavi Ganipineni,  Université catholique de Louvain, Advanced Drug Delivery and Biomaterials, Louvain Drug Research Institute, Brussels, Belgium.
   
  “Targeting the SDF-1α/CXCR4 Signalling Axis for Trapping of Glioblastoma Cells”
  Muhammad Haji Mansor, CRCINA, INSERM, Université de Nantes, Université d’Angers, Angers, France.
   
12:15 Lunch
   

14:00 - 14:30

 

"Small is beautiful: Single domain antibodies for cancer diagnostic and therapy"

 

Invited speaker: Patrick Chames, CRCM, Cancer Research Center of Marseille, UMR INSERM 1068 CNRS 7258, Marseille, France.

   
14:30 - 15:30 “Inhibition of heparanase-mediated tumor progression by natural sulfated polysaccharide derivatives”
  Rémi Cousin, UMR CNRS 7266 LIENSs, BCBS group (Biotechnologies and Chemistry applied to Bioressources for health), University of La Rochelle, France.
   
  “Hypoxia imaging: interest of Image-Guided Radiotherapy for the treatment of brain metastases from lung cancer, a preclinical study”
  Aurélien Corroyer-Dulmont, Normandie Univ, UNICAEN, CEA, CNRS, ISTCT laboratory/CERVOxy group, Caen, France.
   
  “Theranostic agents for TEM1 targeting: towards clickable radioimmunoconjugates“
  Alice D’Onofrio, Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Portugal.
   
15:30 - 16:00 Coffee break
   

16:00 - 17:00

 

“Preclinical CDK4/6 inhibition for Squamous Cell Carcinoma of the Head and Neck (SCCHN)“
  Gabrielle van Caloen, Institut de Recherche Clinique et Expérimentale (MIRO), Université Catholique de Louvain, Brussels, Belgium.
   
  “CD38: a promising marker for immuno-PET imaging of MM”
  Benjamin Chalopin, CRCINA, INSERM, CNRS, Université d’Angers, Université de Nantes, Nantes, France.
   
  “Optimization of ADAPT6, a new scaffold protein-based probe for radionuclide molecular imaging of cancer“
  Javad  Garousi, Uppsala University, Uppsala, Sweden.
   
17:00 - 23:00 Social event

Saturday September 29th

Session 3: Input of imaging in the follow-up of a tumour targeting & Advances of multimodality for imaging and therapy

9:00 - 9:30

 

“Integrating PET imaging with Nanomedicine for gammadelta T-cell Immunotherapy”

  Invited speaker: Rafael T.M. de Rosales, Division of Imaging Sciences and Biomedical Engineering, King's College London, St. Thomas' Hospital, London, United-Kingdom.
   
9:30 - 10:30 “Intracranial gliobalstoma follow-up study by multimodal imaging methods”
  Nikolett Hegedűs, Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary.
   
  “Stable and inert lanthanide(III) complexes with pyclen-based ligand bearing picolinate arms for liver cancer diagnostic and therapy“
  Gwladys NizouUniversité de Bretagne Occidentale, UMR-CNRS 6521, IBSAM, UFR des Sciences et Techniques, Brest, France.
   
  “Multimodal nanoemulsions for whole-body imaging in metastatic cancer”
  Sandra Díez-Villares, Nano-Oncology Unit, Translational Medical Oncology Group (ONCOMET). Health Research Institute of Santiago de Compostela (IDIS) and CIBERONC, Santiago de Compostela, Spain.
   
10:30 - 10:50 Poster session & Coffee break
   

10:50 - 11:50

 

“In vitro and in vivo trackable titanocene-based complexes using optical imaging or SPECT”
 

Océane Florès, ICMUB, UMR 6302 CNRS, Université de Bourgogne, Dijon, France.

   
 

“New Cu(II)-based monopicolinate cyclam derivatives for theranostic PET/PDT applications”

 

Jonathan Mendy, Université de Bretagne Occidentale, UMR-CNRS 6521, IBSAM, UFR Sciences et Techniques, Brest, France.

   
 

“Au@DTDTPA(Gd)-Cy5 nanoparticles for multimodality imaging in a Triple Negative Breast Cancer (TNBC) model“

  Océane Campion, Université de Reims Champagne-Ardenne, UFR Sciences Exactes et Naturelles & CNRS UMR 7369, MEDyC, Reims, France.
   
12:00 Lunch
   
13:10 End of the workshop - Departure

Other informations

Scientific sessions:

- Duration of selected talks is 20 minutes incl. questions.

 

Poster session:

- The format of poster is A0.

- Discussion around the posters will be possible during all coffee breaks. Posters should therefore be hanged for the entire duration of the workshop.